Apnimed Posts $125.9M Q2 Profit, FDA Accepts NDA for OSA Drug with Feb 2027 PDUFA Date
APMD sits 29% above its 52-week low of $22.35.
Summary
Apnimed reported Q2 2026 net income of $125.9 million, driven by a $85.4 million gain on sale of its equity method investment and a $57.1 million reversal of deposit liability. The company also announced FDA acceptance of its NDA for AD109 (Oxnimbi) with a PDUFA target action date of February 28, 2027. Cash and equivalents stood at $172.8 million as of June 30, 2026, before the $220.8 million IPO proceeds. Additional corporate updates include a $150 million senior secured credit facility, $100 million upfront from monetizing its Shionogi-Apnimed Sleep Science interest, and inclusion in the preliminary Russell 2000 Index additions effective September 21, 2026. The FDA acceptance and PDUFA date are the key catalysts for the stock, as Oxnimbi targets an estimated 80 million U.S. OSA patients. The company will present at the Cantor Global Healthcare Conference on September 10, 2026.
At the time of this announcement, APMD was trading at $28.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $22.35 to $35.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.